Has Sivan Kinberg received payments from drug or device companies?

Yes. Drug and device makers reported $261,495 in general payments to Sivan Kinberg across 275 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sivan Kinberg did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sivan Kinberg come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sivan Kinberg

Pediatric Gastroenterology · New York, NYNPI 1508195637

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $175,585 of the $261,495 with a category attached, or 67.1%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 73.0% of it on its own, with 6 other manufacturers making up the rest. Among pediatric gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$261,495in general payments, 2019–2025

Across 275 payments — averaging $950.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$191K
Alcresta Therapeutics, Inc.$36K
Fresenius Kabi USA, LLC$28K
Baxter Healthcare$7K
Ipsen Biopharmaceuticals, Inc$150
Ironwood Pharmaceuticals, Inc$125
plus $27 from 1 others

$9,451in research payments, 2019–2025

Across 3 payments — averaging $3150.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Vectivbio AG$7K
Takeda Pharmaceuticals U.S.A., Inc.$2K

What the payments were for

Consulting fees$50,97319%
Speaking & faculty fees$175,58567%
Travel & lodging$22,1228%
Food & beverage$6,3152%
Education$6,5002%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	175	$190,790
Alcresta Therapeutics, Inc.	42	$35,647
Fresenius Kabi USA, LLC	53	$27,972
Baxter Healthcare	2	$6,785
Ipsen Biopharmaceuticals, Inc	1	$150
Ironwood Pharmaceuticals, Inc	1	$125
QOL Medical, LLC	1	$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$261,495 in reported general payments places this provider in the 95th percentile of 143 pediatric gastroenterology providers in New York.

See all pediatric gastroenterology providers in New York →

Other pediatric gastroenterology in New York

Mirna ChehadeNew York$217K
Michael DolingerNew York$191K
Thomas WallachNew York$160K
Neal LeleikoNew York$157K
John BucuvalasNew York$20K
Julie KhlevnerNew York$15K
Joanne LaiNew York$10K
Jaime ChuNew York$4K
Elizabeth SpencerNew York$3K
Robbyn SockolowNew York$3K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →